| Zosano Pharma is a clinical stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using its proprietary intracutaneous microneedle system (the System). Co.'s development activities are focused on its product candidate, Qtrypta (M207). Qtrypta (M207) is Co.'s proprietary formulation of zolmitriptan delivered utilizing its System. Zolmitriptan is one of a class of serotonin receptor agonists known as triptans and is used as an acute treatment for migraine. Qtrypta (M207) is designed for absorption of zolmitriptan into the bloodstream without dependence on the gastrointestinal tract. We show 20 historical shares outstanding datapoints in our coverage of ZSAN's shares outstanding history.|
Understanding the changing numbers of ZSAN shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ZSAN versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ZSAN by allowing them to research ZSAN shares outstanding history
as well as any other stock in our coverage universe.